FDA approves Ironwood's combination gout treatment

04:38 EDT 22 Aug 2017 | Pharmafile

Ironwood Pharmaceuticals has announced that the FDA has approved its drug Duzallo for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone.

While the drug was given the go-ahead in this indication, the FDA noted that it is not suitable for asymptomatic hyperuricemia.

read more

Original Article: FDA approves Ironwood's combination gout treatment


More From BioPortfolio on "FDA approves Ironwood's combination gout treatment"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....